Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013

Benzer Materyaller

• Peripheral arterial disease and type 2 diabetes: Older patients still exhibit a survival benefit from glucose control
  Yazar:: Höbaus, Clemens, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010
  Yazar:: Schernthaner, Guntram, ve diğerleri
  Baskı/Yayın Bilgisi: (2011)
• Effect of Pioglitazone on Cardiovascular Outcome in Diabetes and Chronic Kidney Disease
  Yazar:: Schneider, Christian A., ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
  Yazar:: Schernthaner, Guntram, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Do We Still Need Doctors?
  Yazar:: Larcher, Victor
  Baskı/Yayın Bilgisi: (1998)